Formerly a subsidiary of Ambion, Inc, in March 2021 it was reported that Asuragen had been acquired by Minneapolis based, Bio-Techne (NASDAQ:TECH). Asuragen functions as a fully integrated diagnostic development company and pharmaceutical services provider with special capabilities in the area of mRNA and miRNA. SBIR-involved since the very early days after founding, the Companyâs diagnostic product portfolio consists of the first-ever validated microRNA diagnostic assay for pancreatic cancer, quantitative RNA tests for leukemia gene translocations, innovative genetic testing solutions for the fragile X mental retardation (FMR1) gene, Signature® Oncology products for the qualitative detection of gene translocations and mutations in a variety of hematological and solid tumors, RNA stabilization technologies, and industry-leading controls and standards engineered using its patented Armored RNA technology. Asuragen is empowered with a high level of scientific expertise and assay development capabilities, CLIA and GLP testing services, and an established cGMP manufacturing facility, which allow it to span the spectrum of discovery, testing, production and commercialization for companion diagnostic
